Skye Bioscience Stock Forecast
NASDAQ: SKYEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
SKYE analyst consensus
Consensus (4 analysts)
none
Avg. price target
$68.00+3947.62%
- Strong buy 0
- Buy 2
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 4 Wall Street analysts covering Skye Bioscience (2026-10-09), 2 rate the stock a buy or strong buy, 2 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $68.00, with a high estimate of $160.00 and a low estimate of $16.00. The average target implies upside of 3947.6% from the current price of $1.68.
The spread between the highest and lowest targets is 900.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for SKYE.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 2 | 50% |
| Hold | 2 | 50% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $16.00 | +852.38% |
| Average target | $68.00 | +3947.62% |
| High target | $160.00 | +9423.81% |